<DOC>
	<DOCNO>NCT00049751</DOCNO>
	<brief_summary>The purpose study evaluate safety collect serious adverse event subject moderately severely active rheumatoid arthritis unable obtain etanercept failed one prior disease-modifying antirheumatic drug ( DMARDs ) .</brief_summary>
	<brief_title>Study Human Anti-TNF Monoclonal Antibody D2E7 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion : Subjects must meet ACR criterion diagnosis RA least 3 month , must meet ACR Functional Class I , II III ( 1992 criterion ) must confirm diagnosis active moderate severe rheumatoid arthritis define 6 swollen joint 9 tender joint ; must also DAS 3.2 great study entry , normal laboratory parameter ESR &gt; 20 , satisfactory response intolerance one prior DMARDs willing able give inform consent . Exclusion : Previous treatment total lymphoid irradiation antiCD4 CAMPATH 1H monoclonal antibody result persistent CD4 lymphopenia , history acute inflammatory joint disease RA , prior treatment cyclophosphamide chlorambucil , prior treatment intravenous immunoglobulin within 70 day , history malignant lymphoma , history uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease stroke , positive HIV status , positive serology Hepatitis B C , previous history tuberculosis listeria infection , previous history cancer successfully treat skin cancer ; woman pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>